Poster presentation during AACR annual meeting 2022
Antitumor activity of a novel allogeneic colorectal cancer vaccine in C57BL/6 mice bearing MC38 anti-PD1 resistant colon carcinoma syngeneic model with TME
Céline Gongora, Elsa Kress, Claudine Vermot-Desroches, Lionel Chalus, Jeremy Forget, Benoît Pinteur, Paul Bravetti, Charles Dumontet, Antoîne Italiano; Abstract 2051: Antitumor activity of a novel allogeneic colorectal cancer vaccine in C57BL/6 mice bearing MC38 anti-PD1 resistant colon carcinoma syngeneic model with TME. Cancer Res 15 June 2022; 82 (12_Supplement): 2051. https://doi.org/10.1158/1538-7445.AM2022-2051
19 January 2023
Paul Bravetti (Brenus CEO) & Jan Lichtenberg (InShpero CEO) interview about the collaborative project ALLOGENIX granted by the European Comission supporting the development of a companion test for the next-generation cancer cell immunotherapy STC-1010.
16 May 2022
“Brenus Pharma designs a shield against resistant cancer cells”
To pursue R&D and finalize preclinical studies of the first candidate targeting metastatic colorectal cancer, Brenus Pharma has just completed a seed round of €4 million seed round involving: Jacques Gardette's familly office of Jacques Gardette, Biojag ; Bpifrance and the Caisse d'épargne Auvergne Limousin.
16 February 2022
“An anti-cancer shield created for each patient”
Brenus Pharma Story telling & closing of first financing round (€4M) & Added value of Brenus therapy compared to other treatments.
29 November 2022
Poster presentation during SITC annual meeting 2022
[CAM MODEL - STC1010 Efficacy prediction & MoA Validation]